Compare Spago Nanomedical AB with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
SEK 79 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
-0.97
-86.37%
2.58
Revenue and Profits:
Net Sales:
0 Million
(Quarterly Results - Dec 2025)
Net Profit:
-6 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
2.43%
0%
2.43%
6 Months
-25.91%
0%
-25.91%
1 Year
-35.28%
0%
-35.28%
2 Years
-46.82%
0%
-46.82%
3 Years
-79.75%
0%
-79.75%
4 Years
-95.61%
0%
-95.61%
5 Years
0%
0%
0.0%
Spago Nanomedical AB for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
1.92%
EBIT Growth (5y)
-14.24%
EBIT to Interest (avg)
-38.27
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.04
Sales to Capital Employed (avg)
0.05
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
5.81
EV to EBIT
-2.47
EV to EBITDA
-2.49
EV to Capital Employed
89.42
EV to Sales
58.79
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-3615.50%
ROE (Latest)
-166.75%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Mildly Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
No Trend
Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ
Dec'25
Sep'25
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-6.90
-7.40
6.76%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-5.90
-6.30
6.35%
Operating Profit Margin (Excl OI)
-1,724,250.00%
-529,142.90%
-1,19,510.71%
USD in Million.
Net Sales
QoQ Growth in quarter ended Dec 2025 is 0.00% vs -100.00% in Sep 2025
Consolidated Net Profit
QoQ Growth in quarter ended Dec 2025 is 6.35% vs 10.00% in Sep 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
0.40
1.90
-78.95%
Operating Profit (PBDIT) excl Other Income
-30.70
-38.10
19.42%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-26.60
-32.50
18.15%
Operating Profit Margin (Excl OI)
-70,627.00%
-20,084.20%
-5,054.28%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is -78.95% vs 58.33% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 18.15% vs 22.99% in Dec 2024
About Spago Nanomedical AB 
Spago Nanomedical AB
Pharmaceuticals & Biotechnology
Spago Nanomedical publ AB, formerly Spago Imaging publ AB, is a Sweden-based biotechnology company. It specialized in the areas of contrast agents and nanoscale life science research. The Company is involved in three projects: Spago Pix, a nanomaterial developed for use as a cancer selective contrast agent for Magnetic Resonance Imaging (MRI); the therapeutic project Tumorad, using nanoparticles loaded with radionuclides for selective treatment of cancers, which are unsuitable for surgery or external radiation; and Archaea Platin, aimed at delivering of chemotherapeutic substance cisplatin selectively to tumors in order to reduce side effects on healthy tissue. The Company's technology comprises a technology platform IonXgel, which is a nano-sized biocompatible material consisting of polar polymers; a protein-based drug delivery platform, ProtRc; and 3PEG, a platform which enables attachment of polyethylene glycol (PEG) derivatives to small molecules (PEGylation).
Company Coordinates 
Company Details
Scheelevagen 22 , LUND None : 223 63
Registrar Details






